NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
Clinical Trials
7 trialsNCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01466036 2024-03-05
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01822522 2023-01-10
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
Phase 1 Completed
NCT01588821 2020-09-29
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Phase 2 Completed
NCT01428219 2017-12-12
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01738438 2016-12-06
Cabozantinib for Metastatic Triple Negative BrCa
Dana-Farber Cancer Institute
Phase 2 Completed